產(chǎn)品目錄

規(guī)格	5 mg 10 mg 25 mg
CAS	2240176-35-4
別名	N/A
化學(xué)名	N/A
分子式	C64H82N18O13 • XCF3COOH
分子量	1311.4
溶解度	DMF: 10mg/mL,DMSO: 3mg/mL,PBS (pH 7.2): 3mg/mL
儲(chǔ)存條件	-20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

產(chǎn)品描述：

Triptorelin is a synthetic gonadotropin-releasing hormone (GnRH) peptide agonist that binds to the GnRH receptor (GnRHR; Ki = 0.3 nM in CHO cells expressing the human receptor).1 It inhibits the growth of DU145, LNCaP, and PC3 prostate and OVCAR-3 ovarian cancer cells (IC50s = 62.1, 73.4, 98.1, and 67.7 μM, respectively).2 Triptorelin also inhibits the growth of the triple-negative breast cancer (TNBC) cell lines HCC1806 and MDA-MB-231 (EC50s = 58.29 and 31.59 μM, respectively).3 It stimulates follicle stimulating hormone (FSH) and luteinizing hormone (LH) release from primary rat pituitary cells when used at a concentration of 50 nM.2 It also decreases tumor volume of Dunning R3327H prostate tumor flank implants and reduces prostate and testis weight in rats when administered at a dose of 1 mg/kg per day.4 Formulations containing triptorelin have been used in the palliative treatment of advanced prostate cancer.

1.Nederpelt, I., Georgi, V., Schiele, F., et al.Characterization of 12 GnRH peptide agonists - a kinetic perspectiveBr. J. Pharmacol.173(1)128-141(2016) 2.Varamini, P., Rafiee, A., Giddam, A.K., et al.Development of new gonadotropin-releasing hormone-modified dendrimer platforms with direct antiproliferative and gonadotropin releasing activityJ. Med. Chem.60(20)8309-8320(2017) 3.Kwok, C.W., Treeck, O., Buchholz, S., et al.Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC)Target Oncol.10(3)365-373(2015) 4.Princivalle, M., Broqua, P., White, R., et al.Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonistJ. Pharmacol. Exp. Ther.320(3)1113-1118(2007)

特別提醒：

1. 本產(chǎn)品僅供科研使用。請(qǐng)勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請(qǐng)勿存放于普通住宅區(qū)。

2. 為了您的安全和健康，請(qǐng)穿好實(shí)驗(yàn)服并佩戴一次性手套和口罩操作。

原創(chuàng)作者：上海莼試生物技術(shù)有限公司

在線(xiàn)咨詢(xún)

留言注意事項(xiàng)：

1.遵守中華人民共和國(guó)有關(guān)法律、法規(guī)，尊重網(wǎng)上道德，承擔(dān)一切因您的行為而直接或間接引起的法律責(zé)任。

2.請(qǐng)您真實(shí)的反映產(chǎn)品的情況,不要捏造、誣蔑、造謠。如對(duì)產(chǎn)品有任何疑問(wèn),也可以留言咨詢(xún)。

3.未經(jīng)本站同意，任何人不得利用本留言簿發(fā)布個(gè)人或團(tuán)體的具有廣告性質(zhì)的信息或類(lèi)似言論。

您感興趣的產(chǎn)品*
您的單位*
聯(lián)系人*
聯(lián)系電話(huà)*
詳細(xì)地址*
常用郵箱*
請(qǐng)輸入您對(duì)我們的意見(jiàn)或建議*
驗(yàn)證碼*